Liposomal Bupivacaine in Implant-Based Breast Reconstruction

Area of Science:

• Plastic Surgery
• Anesthesiology
• Pharmacology

Background:

• Implant-based breast reconstruction is a common procedure.
• Effective pain management is crucial for patient recovery and satisfaction.
• Traditional pain management strategies can lead to significant opioid consumption and prolonged hospital stays.

Purpose of the Study:

• To evaluate the efficacy of liposomal bupivacaine in managing pain after implant-based breast reconstruction.
• To compare the impact of liposomal bupivacaine versus standard bupivacaine on opioid and benzodiazepine consumption.
• To assess the effect on length of hospital stay and associated costs.

Main Methods:

• Prospective, randomized, single-blind trial.
• Comparison of liposomal bupivacaine with standard bupivacaine in the breast pocket.
• Monitoring of pain scores, medication consumption (opioids, benzodiazepines, anti-emetics), length of stay, and hospital charges.

Main Results:

• No significant difference in postoperative pain scores between groups.
• Liposomal bupivacaine group showed significantly lower opioid consumption (0.76 vs 1.43 MSED/h).
• Reduced benzodiazepine use (0.176 vs 0.348 mg/h), shorter hospital stay (29.8 vs 46.7 hours), and lower hospital charges ($10,828 vs $18,632) in the liposomal bupivacaine arm.

Conclusions:

• Liposomal bupivacaine effectively reduces the need for opioid and benzodiazepine medications post-breast reconstruction.
• The use of liposomal bupivacaine is associated with a shorter hospital stay and decreased healthcare costs.
• These findings support the integration of liposomal bupivacaine into enhanced recovery protocols for implant-based breast reconstruction.